The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Anthropic said its powerful new AI model, Mythos, could be dangerous in the wrong hands. WSJ’s Nicole Nguyen explains why and shares some cybersecurity tips for the average tech user. Photo: Sean ...

As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends on ...

Minecraft master Shark compares Java and Bedrock editions to test their differences in Minecraft. Coffee found to have startling effect on aging, says new study An asteroid exploded over Russia - and ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Editor's note: Follow the Rousey vs Carano card live Saturday with updates, results and analysis. Just one more sleep until Ronda Rousey takes on Gina Carano in the highly anticipated return to MMA ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...

Elon Musk, famously a man with big ideas, is building a semiconductor plant vast enough to power those ambitions. Musk on Saturday announced what he calls the "Terafab," a semiconductor manufacturing ...

JDK 26 moves to general production availability. This short-term release is backed by six months of Premier-level support. Java Development Kit (JDK) 26, the latest standard Java release from Oracle, ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...